Invivyd, Inc. (IVVD)

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd doses first participants in Phase 3 COVID-19 trial

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

Invivyd to Participate in Upcoming Investor Events

Invivyd to Participate in Upcoming Investor Events